Shots:
- Abbott has received approval in the US & and CE mark for XIENCE stents, the shortest approved DAPT labeling as short as 28 days in patients with high bleeding risk. XIENCE Skypoint stent also received FDA approval in the US and CE Mark in the EU
- Additionally, patients with stents are typically on DAPT regimens (aspirin and P2Y12 inhibitors) for 6 -12mos. to prevent blood clots from blocking the stented vessel
- Abbott’s XIENCE 28 and XIENCE 904 studies showed that DAPT can be safely discontinued early as short as 28 days with no increased risk in patients’ AEs
Click here to read full press release/ article | Ref: Abbott | Image: Medical Device and Diagnostic Industry
The post Abbott’s XIENCE Stent Receives the US FDA’s Approval for Shortest Blood Thinner Course in Patients with High Bleeding Risk first appeared on PharmaShots.
